Novartis’ Revolade proved effective for seniors

Novartis’ Revolade proved effective for seniors

"Novartis Korea said Tuesday additional data analysis from its EXTEND clinical trial for Revolade (ingredient: eltrombopag) proved it safe and effective for those 65 years and older with idiopathic thrombocytopenic purpura (ITP).

The sub-set study findings were presented at the first International Congress of BMT symposium held in Seoul on Aug. 26.

Revolade (known as Promacta in the U.S.) was developed by GlaxoSmithKline (GSK) and transferred to Novartis노바티스 when it acquired the former’s oncology portfolio."

- By Marian Chu, Korea Biomedical Review

Read More

 

 

back to top

BBB Cleveland logoGuideStar Seal - 2017 goldNORD Member Badge 2018THSNA logo